Skip to Content

Join the 'Ferric Citrate' group to help and get support from people like you.

Ferric Citrate News

Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

Posted 17 Nov 2014 by Drugs.com

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients." For more information about Auryxia, please visit www.Auryxia.com. About End Stage ... Read more

Related support groups: Hyperphosphatemia of Renal Failure, Ferric Citrate

Ask a Question

Further Information

Related Condition Support Groups

Hyperphosphatemia of Renal Failure

Related Drug Support Groups

Auryxia

Ferric Citrate Patient Information at Drugs.com